Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Santhera to File Rolling New Drug Application for Duchenne Treatment to US FDA in Early 2022

12/06/2021 | 01:31am EST


ę MT Newswires 2021
All news about SANTHERA PHARMACEUTICALS HOLDING AG
01/04Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare..
DJ
01/04Santhera Pharmaceuticals Enters into Exclusive License Agreement with Sperogenix for Va..
CI
2021Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Me..
DJ
2021Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Me..
AQ
2021Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 20 million..
CI
2021Santhera to Host Investor Conference Call, Looking Ahead to 2022
AQ
2021Santhera to File Rolling New Drug Application for Duchenne Treatment to US FDA in Early..
MT
2021Santhera to Host Investor Conference Call — Looking Ahead to 2022
AQ
2021Santhera's Board Calls Extraordinary General Meeting To Vote On Future Fundraisings
MT
2021Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Appr..
DJ
More news
Financials
Sales 2021 8,00 M 8,78 M 8,78 M
Net income 2021 -40,0 M -43,9 M -43,9 M
Net Debt 2021 - - -
P/E ratio 2021 -1,92x
Yield 2021 -
Capitalization 59,6 M 65,3 M 65,4 M
Capi. / Sales 2021 7,45x
Capi. / Sales 2022 1,12x
Nbr of Employees 86
Free-Float 81,8%
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | SANN | CH0027148649 | MarketScreener
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,42 CHF
Average target price 6,50 CHF
Spread / Average Target 358%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Elmar J. Schnee Chairman
Martin Gertsch Vice Chairman
Philipp Gutzwiller Independent Director